Clover Health Investments Analyst Price Targets

Wall Street analyst price targets and consensus rating for Clover Health Investments (CLOV).

Price Target Range — 7 Quarters

Analyst Consensus — 4 Analysts

2Buy

2Hold

Consensus RatingBuy# Analysts4Avg. Consensus PT$5Upside to Avg. PT-0.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 6, 2026	UBS	Jonathan Yong	PT Raise	Neutral	$5→$5
Jul 21, 2026	Canaccord Genuity	Richard Close	PT Raise	Buy	$4→$6
Jun 11, 2026	UBS	Jonathan Yong	PT Raise	Neutral	$3→$5
Jun 4, 2026	Canaccord Genuity	Richard Close	PT Raise	Buy	$3→$4
Mar 20, 2026	Canaccord Genuity	Richard Close	PT Cut	Buy	$4→$3
Mar 5, 2026	Leerink Partners	Whit Mayo	PT Cut	Market Perform	$3→$3
Jan 20, 2026	Canaccord Genuity	Richard Close	Maintained	Buy	$4
Nov 6, 2025	Canaccord Genuity	Richard Close	PT Cut	Buy	$4→$4
Aug 7, 2025	Canaccord Genuity	Richard Close	PT Cut	Buy	$5→$4
Aug 6, 2025	UBS	Jonathan Yong	PT Cut	Neutral	$5→$3
Mar 3, 2025	Canaccord Genuity	Richard Close	PT Raise	Buy	$4→$5
Dec 17, 2024	Craig-Hallum	Matt Hewitt	Initiate	Buy	$6
Oct 7, 2024	UBS	Jonathan Yong	Initiate	Neutral	$4

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
UBS Maintains Neutral on Clover Health Investments, Raises Price Target to $5

UBS analyst Jonathan Yong maintains Clover Health Investments (NASDAQ:CLOV) with a Neutral and raises the price target from $4.75 to $5.

Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on Clover Health Investments, Raises Price Target to $5.5

Canaccord Genuity analyst Richard Close maintains Clover Health Investments (NASDAQ:CLOV) with a Buy and raises the price target from $4.2 to $5.5.

Benzinga Newsdesk

PRO
UBS Maintains Neutral on Clover Health Investments, Raises Price Target to $4.75

UBS analyst Jonathan Yong maintains Clover Health Investments (NASDAQ:CLOV) with a Neutral and raises the price target from $2.75 to $4.75.

Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on Clover Health Investments, Raises Price Target to $4.2

Canaccord Genuity analyst Richard Close maintains Clover Health Investments (NASDAQ:CLOV) with a Buy and raises the price target from $3.2 to $4.2.

Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on Clover Health Investments, Lowers Price Target to $3.2

Canaccord Genuity analyst Richard Close maintains Clover Health Investments (NASDAQ:CLOV) with a Buy and lowers the price target from $3.7 to $3.2.

Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on Clover Health Investments, Maintains $3.7 Price Target

Canaccord Genuity analyst Richard Close maintains Clover Health Investments (NASDAQ:CLOV) with a Buy and maintains $3.7 price target.

Benzinga Newsdesk

Clover Health Investments Corp

뉴스

파트너 / 기고자

벤징가 글로벌

Clover Health Investments Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
UBS Maintains Neutral on Clover Health Investments, Raises Price Target to $5

PRO
Canaccord Genuity Maintains Buy on Clover Health Investments, Raises Price Target to $5.5

PRO
UBS Maintains Neutral on Clover Health Investments, Raises Price Target to $4.75

PRO
Canaccord Genuity Maintains Buy on Clover Health Investments, Raises Price Target to $4.2

PRO
Canaccord Genuity Maintains Buy on Clover Health Investments, Lowers Price Target to $3.2

PRO
Canaccord Genuity Maintains Buy on Clover Health Investments, Maintains $3.7 Price Target

People Also Watch

People Also Watch

Clover Health Investments Corp

뉴스

파트너 / 기고자

벤징가 글로벌

Clover Health Investments Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROUBS Maintains Neutral on Clover Health Investments, Raises Price Target to $5

PROCanaccord Genuity Maintains Buy on Clover Health Investments, Raises Price Target to $5.5

PROUBS Maintains Neutral on Clover Health Investments, Raises Price Target to $4.75

PROCanaccord Genuity Maintains Buy on Clover Health Investments, Raises Price Target to $4.2

PROCanaccord Genuity Maintains Buy on Clover Health Investments, Lowers Price Target to $3.2

PROCanaccord Genuity Maintains Buy on Clover Health Investments, Maintains $3.7 Price Target

People Also Watch

People Also Watch

PRO
UBS Maintains Neutral on Clover Health Investments, Raises Price Target to $5

PRO
Canaccord Genuity Maintains Buy on Clover Health Investments, Raises Price Target to $5.5

PRO
UBS Maintains Neutral on Clover Health Investments, Raises Price Target to $4.75

PRO
Canaccord Genuity Maintains Buy on Clover Health Investments, Raises Price Target to $4.2

PRO
Canaccord Genuity Maintains Buy on Clover Health Investments, Lowers Price Target to $3.2

PRO
Canaccord Genuity Maintains Buy on Clover Health Investments, Maintains $3.7 Price Target